share_log

RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $6

Benzinga ·  Nov 11, 2023 03:33

RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target from $7 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment